INDV
Indivior Pharmaceuticals, Inc.
Next earnings Jul 29, 2026 · consensus $0.89 EPS, $313M rev
Last earnings +7.7% on 2026-04-30
$41.83
▲ +1.31%$41.83▲ +199.86%
over 1Y
L $13.69EODHDH $41.83
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+1.3%
1W+9.2%
1M+12.7%
3M+44.4%
YTD+17.1%
1Y+199.9%
Hold
Conviction
Horizon
Medium (3–12mo)
12-mo target
$•••
Street · 12 analysts
Buy
Addiction-treatment maker's profits rebounded sharply as litigation clears, but negative equity, cash burn and residual opioid claims temper the turn.
Revenue (FY2025) $1.24B · FY2025
The read
Middling fundamentals offset by an attractive price (~49% below fair value) — worth a look on the value angle.
Indivior is a specialty pharma focused on opioid-use-disorder treatment, anchored by the long-acting injectable Sublocade and the Suboxone franchise. FY2025 marks a sharp earnings recovery: revenue grew 4.3% to $1.24B (gross margin a rich 80.2%), but the real story is below the gross line — litigation settlement expense collapsed to $3M from $195M in FY2024 and $239M in FY2023, allowing operating income to surge to $262M (from $38M) and net income to jump to $210M (diluted EPS $1.64) from just $7M. The multi-year litigation overhang that produced losses (-$126M in FY2023) and crushed the balance sheet is now largely resolved, and that is what drove the profitability inflection.
Financials · annual, by fiscal year
| Line item | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|
| Revenue | $901M | $1.09B | $1.19B | $1.24B |
| Gross profit | $749M | $919M | $957M | $994M |
| Operating income | -$81.0M | -$152M | $38.0M | $262M |
| Net income | -$44.0M | -$126M | $7.00M | $210M |
| Diluted EPS | -$0.32 | -$0.92 | $0.05 | $1.64 |
| Net margin | -4.9% | -11.5% | 0.6% | 16.9% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$5.36B
EV / EBITDA19.7
EV / Sales4.3
EV / FCF—
P / FCF—
PEG (trailing)0.01
Earnings yield4.0%
FCF yield-1.8%
Quality & risk
ROIC (est.)—
Free cash flow-$93.0M
Total debt$319M
Net cash-$124M
Altman Z-Score3.62 safe
Piotroski F-Score3/9
Capital returns
Buyback yield0.2%
Dividend yield (est.)—
Shareholder yield0.2%
Shares Δ YoY+0.3%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsRed flag in recent filings — agreement terminated (2026-03-17). Worth a closer look.
Recent filings
all on EDGAR ↗4Period ending 2026-06-222026-06-23open ↗4Period ending 2026-06-112026-06-12open ↗144Filing2026-06-11open ↗4Period ending 2026-06-082026-06-10open ↗144/AFiling2026-06-08open ↗144Filing2026-06-08open ↗8-KPeriod ending 2026-05-132026-05-15open ↗SCHEDULE 13G/AFiling2026-05-15open ↗4Period ending 2026-05-122026-05-14open ↗4Period ending 2026-05-132026-05-14open ↗4Period ending 2026-05-132026-05-14open ↗4Period ending 2026-05-132026-05-14open ↗
Frequently asked
- Is Indivior Pharmaceuticals, Inc. (INDV) a buy?
- INDV currently carries a Hold rating with 3/5 conviction, derived from its latest SEC filings. Addiction-treatment maker's profits rebounded sharply as litigation clears, but negative equity, cash burn and residual opioid claims temper the turn.
- What is INDV's fair value?
- A Modified-Graham model based on INDV's SEC fundamentals estimates a fair value of about $62.32. It is an estimate from reported earnings, not a price target.
- Is INDV overvalued or undervalued?
- Against a Modified-Graham fair-value estimate, INDV currently appears undervalued relative to its SEC-grounded earnings power.
- What is Indivior Pharmaceuticals, Inc.'s quality score?
- INDV scores 64.42156862745097/100 (grade C+) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001625297, latest 10-Q filed 2026-04-30) · EODHD · analysis by claude-code · as of 6/21/2026, 9:06:16 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.